Cantitate/Preț
Produs

2020 Nelson's Pediatric Antimicrobial Therapy

Autor John S. Bradley, John D. Nelson, Elizabeth Barnett
en Limba Engleză Paperback – 15 ian 2020
The 26th edition provides practical, evidence-based recommendations from the experts in antimicrobial therapy for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help health care providers select the best of all antimicrobial choices.

Drug descriptions cover pediatric-appropriate antimicrobial agents available today and include complete information about dosing regimens.

New in the 26th edition:
  • First pediatric approval of beta-lactam/beta-lactamase inhibitor for CRE (carbapenem-resistant enteric bacilli), ceftazidime-avibactam
  • Replacement antibiotics for cefotaxime (lack of availability in the US), including ceftriaxone and cefepime (for neonates)
  • Situations in which ceftaroline is preferred over vancomycin by the Editors for MRSA infections
  • Updates on management of influenza, including baloxavir (now approved for children >12 years)
  • New approaches to treatment of mucomycosis
  • New recommendations for malaria
  • More than 150 new references

Citește tot Restrânge

Preț: 30105 lei

Preț vechi: 31689 lei
-5%

Puncte Express: 452

Preț estimativ în valută:
5768 6262$ 4946£

Carte nepublicată încă

Doresc să fiu notificat când acest titlu va fi disponibil:

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781610023528
ISBN-10: 1610023528
Pagini: 320
Dimensiuni: 123 x 174 x 22 mm
Greutate: 0.27 kg
Ediția:00026
Editura: AMER ACADEMY OF PEDIATRIC

Descriere

The 26th edition provides practical, evidence-based recommendations from the experts in antimicrobial therapy for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help health care providers select the best of all antimicrobial choices.

Drug descriptions cover pediatric-appropriate antimicrobial agents available today and include complete information about dosing regimens.

New in the 26th edition:

  • First pediatric approval of beta-lactam/beta-lactamase inhibitor for CRE (carbapenem-resistant enteric bacilli), ceftazidime-avibactam
  • Replacement antibiotics for cefotaxime (lack of availability in the US), including ceftriaxone and cefepime (for neonates)
  • Situations in which ceftaroline is preferred over vancomycin by the Editors for MRSA infections
  • Updates on management of influenza, including baloxavir (now approved for children >12 years)
  • New approaches to treatment of mucomycosis
  • New recommendations for malaria
  • More than 150 new references